Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
Neovasc announced its participation in the 2021 Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Bill Little, the Chief Operating Officer, will present on September 29 at 4:00 pm EDT. A live webcast link will be available on the Neovasc website, with the presentation archived for 90 days. Neovasc is focused on minimally invasive technologies for cardiovascular conditions, including the Neovasc Reducer™ for refractory angina, and Tiara™ for mitral valve disease, currently in clinical investigation.
- None.
- None.
VANCOUVER and MINNEAPOLIS, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021. Bill Little, Neovasc’s Chief Operating Officer, will give a presentation on Wednesday, September 29 at 4:00 pm EDT. A link to the live webcast of the presentation will be available in the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel, and Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2019 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@westwicke.com
FAQ
What event will Neovasc be participating in on September 29-30, 2021?
Who will present for Neovasc at the Benzinga Healthcare Conference?
What time is Neovasc's presentation at the conference?
Where can I watch Neovasc's presentation?
How long will the recording of Neovasc's presentation be available?
What products does Neovasc focus on?
Is the Neovasc Reducer™ commercially available in the U.S.?
In which countries are Neovasc's products under clinical investigation?
